The Pipeline for iPSC-Derived Cell Therapeutics in 2027
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
How Human iPSCs are Revolutionizing Drug Discovery in 2027
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Thankfully, some new medicines are now being tested for safety on specialized cells developed from human pluripotent cell lines. Cell types which are increasingly being used within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2026
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
Interview with Dr. Nianwei Lin, Co-Founder and President of iXCells Biotechnologies
*Sponsored Content: This interview is sponsored by iXcells Biotechnologies.Â
Founded in 2014 and headquartered in San Diego, CA, iXCells Biotechnologies is a cell biology and cell technology company specializing in pre-clinical drug discovery solutions. iXCells provides primary cells and iPSC derived cells, custom iPSC services, and functional bioassay development and execution, among other products and services.
In this interview with Nianwei Lin, Co-Founder and President of iXCells Biotechnologies, we discuss the company’s product pipeline, innovative drug discovery solutions, CRO services, and its future goals. [Read more…]
- 1
- 2
- 3
- …
- 80
- Next Page »




